In line with the launch of the much anticipated online system to enable the electronic submission and management of Special Access Scheme (SAS) scheme in July 2018, which aimed to reduce administrative burden for HCPs in the management of SAS applications and notifications, and increase the accessibility of medicinal cannabis to patients that were in desperate need. The Hydroponics Company (THC) have sponsored a series of educational seminars as part of their strategy to increase engagement with medical and allied healthcare practitioners that wish to know more about the medicinal cannabis industry.
The events included expert knowledge from international speakers such as Dr Jeffrey Hergenrather, an experienced US medical cannabis physician. A seminar was held on the 8th September 2018 by Medicinal Cannabis Education (MCE) on the “Essentials of Medicinal Cannabis: What Practitioners Need to Know” and also included presentations from some of Australia’s leading medicinal cannabis experts.
As part of the THC sponsored event series, a two-day interactive course was provided. Created to educate practitioners who are interested in registering to be able to prescribe medicinal cannabis. The course was designed to provide knowledge on evidence-based medicinal cannabis, its uses, prescribing, herb-drug interactions and other safety issues.
Of the many that showed interest from the medical and wellness community, the main attendees were medical practitioners, GPs, nurses, pharmacists, Chinese medicine practitioners, and naturopaths/western herbal medicine practitioners. As THC are also partners with Endoca, we were also featured at the event, where our medicinal cannabis oils received strong interest from those that attended.
THC’s Chief Executive Officer, Ken Charteris, commented:
“We are pleased to have sponsored a successful practitioner training course run by MCE Medicinal Cannabis Education to improve education on medicinal cannabis, its uses and the processes for prescribing, and to better engage with experienced medicinal cannabis practitioners and the broader medical community to support the development of education for the medicinal cannabis industry in Australia. We have already received strong interest in Endoca’s medicinal cannabis oils as a direct result of attending the course.”
For practitioners who have shown interest in the scheme, gaining more vital information on medicinal cannabis thanks to these educational programs will hopefully encourage more to register. There is still a long way to go in terms of the acceptance of CBD and medicinal cannabis in Australia. However, there is a strong advocacy among Australians that Medical Cannabis should be available to those that need it.
The initial need for this scheme was partly due to the increasing number of requests that were received by the Therapeutic Goods Administration (TGA) for medicinal cannabis products. Previously medical cannabis was only available to a select few suffering with very specific or terminal illnesses. The SAS Online System is sure to make a huge impact in the coming months and years.
The new scheme inspired a partnership between Endoca and THC, in which Endoca CBD oil will be available on prescription by doctors that register through the MCMP. THC’s involvement in the support of medical practitioners through this educational series shows their dedication in supporting this scheme, by bringing more knowledge to those practitioners that have shown interest.
It is the hope of many that this expert lead information will help fuel and inspire more growth within the medical cannabis industry in Australia and bring awareness to the underused but highly in demand natural resource of medicinal cannabis.
If you are interested in knowing more about the MCE’s practitioner training or the SAS scheme, you can read our articles on the Endoca and THC partnership and how to access medical cannabis in Australia. For further information on MCE’s practitioner training and public information events, please visit: http://medicinalcannabiseducation.org.au/
Disclaimer: Views expressed here do not necessarily reflect those of Endoca and its staff. This article is not intended to provide medical advice, diagnosis, treatment or cure. Endoca CBD products have not been approved by the US Food and Drug Administration (FDA).